(Q38995370)

8 September 2017

title

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway (English)

1 reference

8 September 2017

5

Ulrich Keilholz

1 reference

8 September 2017

Alexander Gross

1

1 reference

8 September 2017

Annett Niemetz-Rahn

2

1 reference

8 September 2017

Anika Nonnenmacher

3

1 reference

8 September 2017

Johannes Tucholski

4

1 reference

8 September 2017

Alberto Fusi

6

1 reference

8 September 2017

publication date

15 May 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

10

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

77-84

1 reference

EGFR and cancer prognosis

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Human melanocytes do not express EGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

EGFR in melanoma: clinical significance and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

A phase II study of gefitinib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Erlotinib and bevacizumab have synergistic activity against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

How to make a melanoma: what do we know of the primary clonal events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0318-9

Increasing Epidermal Growth Factor Receptor Expression in Human Melanocytic Tumor Progression

21 January 2018

1 reference

12 December 2020

Epidermal growth factor facilitates melanoma lymph node metastasis by influencing tumor lymphangiogenesis

1 reference

12 December 2020

Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas

1 reference

12 December 2020

Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation

1 reference

12 December 2020

EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis

1 reference

12 December 2020

10.1007/S11523-014-0318-9

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1034588935

0 references

1 reference